Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): 'It Is Worthwhile Speculation'
10 Health Care Stocks Whale Activity In Today's Session
Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma